Open AccessS1127 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Renal Impairment: Week 48 Results From a Phase 2 Open-Label Study
Author(s) -
Harry L.A. Janssen,
Jeong Heo,
Claire Fournier,
Sang Hoon Ahn,
Carla S. Coffin,
怡翔 黃,
Aric Josun Hui,
Magdy Elkhashab,
SyedMohammed Jafri,
Shuyuan Mo,
Jake Winans,
John F. Flaherty,
Anuj Gaggar,
WanLong Chuang,
Ed Gane,
YoungSuk Lim
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000778040.44734.f8
Subject(s) - medicine , tenofovir alafenamide , gastroenterology , dialysis , creatinine , renal function , urology , hbeag , hbsag , hepatitis b , kidney disease , tenofovir , nephropathy , hepatitis b virus , viral load , endocrinology , immunology , virus , diabetes mellitus , antiretroviral therapy , human immunodeficiency virus (hiv)